Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Wanbury Product Launch

Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.

Source

NSE filing, NSE: WANBURY. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Wanbury Ltd: key numbers

Share price
₹174.16
Market cap
₹609.0 Cr
Revenue (annual)
₹650.3 Cr
Net profit (annual)
₹66.13 Cr
P/E (TTM)
10.9×Sector 46.1×
Promoter holding
42.98%-0.04% QoQ
FII holding
0.71%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Wanbury Ltd

All →
13:20 IST NSE
Product Launch

Wanbury Product Launch

Wanbury Skin Health launched its berrysoft baby product range across multiple Indian states. This marks the company's strategic entry into the paediatric dermatology segment.

Other product launch announcements

All →